Enterprise Value

66.81M

Cash

18.78M

Avg Qtr Burn

-5.042M

Short % of Float

2.58%

Insider Ownership

64.41%

Institutional Own.

4.56%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 2

Update

Phase 2

Initiation

TTP273 (Oral GLP-1R) Details
Diabetes, Type 2 diabetes, Cystic fibrosis

Phase 1

Update

TTP488 (Azeliragon) (RAGE) Details
Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder

Failed

Discontinued